Labcorp management check
LH · Health Care · Health Care Services · CEO Adam H. Schechter
Filings as of
5 good · 2 to watch · 0 flagged, across the seven questions below.
- Good
Have owners done well?
Beat its chosen peers$100 invested at the start of fiscal 2021 grew to $150, against $148 for the peer group the company picked itself.
- Good
Does pay follow performance?
Pay rose and fell with returnsOver 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.88 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Watch
What does the CEO cost owners?
2.1% of net income$18.3m of reported pay in fiscal 2025, against $877.0m of net income.
- Watch
Do they own the stock?
CEO stake ≈ 1.8 years of payThe CEO holds 102,565 shares, directly or through trusts (unvested awards not counted): about 1.8 years of pay. Light activity: no buys, $5.0m sold in six months. 6 of 9 sales ran on pre-arranged 10b5-1 plans.
- Good
Are owners being diluted?
Share count shrinkingDiluted shares changed -2.2% a year over the last three fiscal years. Stock-based pay was 0.9% of revenue in the latest year.
- Good
Is leadership stable?
7 leadership filings in 3 yearsCEO in the pay table: Adam H. Schechter. 7 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- Good
Are the books clean?
No red flags on fileNo restatements, auditor changes or late filings since 2021.
Against the S&P 500
Each check's score (0–100) and how it compares: the share of ranked S&P 500 companies it matches or beats, and the median in Health Care.
| Check | Score | At or above | Sector median |
|---|---|---|---|
| Owner returns | 52 | 26 | |
| Pay for performance | 94 | 85 | |
| CEO cost | 23 | 44 | |
| Skin in the game | 48 | 46 | |
| Dilution | 77 | 68 | |
| Stable leadership | 90 | 70 | |
| Clean books | 100 | 100 |
Closest peers
Others in Health Care Services, by management score. Labcorp is 22nd of 60 in its sector.
- 110CICigna76
- 124DVADaVita74
- 192BSXBoston Scientific69
- 194LHLabcorp69
- 219DGXQuest Diagnostics67
- 362CVSCVS Health57
Pay versus performance
From the proxy statement filed April 10, 2026. "Actually paid" values stock awards at the share price, so it rises and falls with the stock.
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | Adam H. Schechter | $18.3m | $30.1m | $4.2m | $150 | $148 | $877.0m |
| 2024 | — | $19.3m | $21.3m | $3.7m | $163 | $147 | $746.0m |
| 2023 | — | $16.0m | $23.8m | $4.1m | $160 | $143 | $418.0m |
| 2022 | — | $14.9m | −$2.3m | $4.4m | $140 | $140 | $1.3bn |
| 2021 | — | $20.6m | $49.7m | $4.7m | $186 | $143 | $2.4bn |
The board says pay is tied most to Adjusted operating income. Its other key measures: Adjusted EPS, Adjusted Operating Income, Revenue, Relative Total Shareholder Return.
Insiders and the CEO's stake
Adam H Schechter (President & CEO) held 102,565 shares directly after their latest Form 4 on Aug 11, 2026, roughly $32.9m at that filing's price.
Light activity: no buys, $5.0m sold in six months. 6 of 9 sales ran on pre-arranged 10b5-1 plans.
- SoldAdam H SchechterPresident & CEO · 10b5-1 plan$3.0mAug 11, 2026
- SoldKerrii B AndersonDirector · 10b5-1 plan$954kAug 17, 2026
- SoldPeter J WilkinsonSVP, Chief Accounting Officer$439kAug 3, 2026
- SoldAmy B. SummyEVP, Chief Marketing Officer$283kAug 4, 2026
Leadership and governance on file
- Aug 14, 2026Leadership change8-K 5.02
- Feb 9, 2026Leadership change8-K 5.02
- Dec 15, 2025Leadership change8-K 5.02
- Dec 10, 2025Leadership change8-K 5.02
- Nov 24, 2025Leadership change8-K 5.02
- May 20, 2025Leadership change8-K 5.02
- Nov 19, 2024Leadership change8-K 5.02
- Sep 11, 2023Leadership change8-K 5.02
- Jun 7, 2023Leadership change8-K 5.02
- May 5, 2023Leadership change8-K/A 5.02
- May 5, 2023Leadership change8-K/A 5.02
- May 4, 2023Leadership change8-K 5.02
Latest shareholder vote results: May 26, 2026, including the say-on-pay vote.
Where the money went
Over 2021–2025: $5.4bn returned to owners in buybacks and dividends, 95% of net income, and $620.9m of pay in stock.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $13.1bn | $11.9bn | $12.2bn | $13.0bn | $14.0bn |
| Net income | $2.4bn | $1.3bn | $418.0m | $746.0m | $877.0m |
| Stock-based pay | $132.9m | $116.8m | $128.7m | $116.7m | $125.8m |
| Buybacks | $1.7bn | $1.1bn | $1.0bn | $250.1m | $450.0m |
| Dividends | — | $195.2m | $254.0m | $243.1m | $240.7m |
| Diluted shares | 98m | 92m | 88m | 84m | 84m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.